See What HealthDay Can Do For You
Contact Us

High Cardiac Troponin T Linked to Reduced Survival

Elevated levels of cardiac troponin T found in nearly 20 percent of percutaneous coronary intervention patients

FRIDAY, Nov. 10 (HealthDay News) -- Elevated levels of cardiac troponin T following percutaneous coronary intervention is associated with reduced survival in patients with normal creatine kinase levels, according to the results of a study published in the Nov. 7 issue of the Journal of the American College of Cardiology.

Abhiram Prasad, M.D., and colleagues from the Mayo Clinic in Rochester, Minn., measured the post-procedure levels of cardiac troponin T -- a marker of myonecrosis -- in 1,949 patients who had undergone percutaneous coronary intervention and had normal pre- and post-procedure levels of creatine kinase-muscle-brain fraction.

The researchers found elevated levels of cardiac troponin T in 19.6 percent of patients, which was associated with significantly higher mortality and higher combined rates of death and myocardial infarction over the median follow-up of 26 months. Elevated cardiac troponin T levels decreased three-year survival from 93.2 percent to 86.9 percent, the investigators report.

"The present report should help refocus the stage light on post-procedural infarction," Neal S. Kleiman, M.D., from Methodist DeBakey Heart Center in Houston, writes in an accompanying editorial. "If we are to continue to reduce the long-term morbidity and mortality in patients who have had interventions, we will need to recognize that there are new markers of risk that merit our attention."

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.